eligibility_summary
Meta10‑19 (CD19 CAR‑T) for R/R B‑cell lymphoma or B‑ALL. Include: consent, CD20+≥2 chemos or PR/MRD after 2, post auto‑HSCT relapse, post‑allo EM or MRD≥0.01%, B‑ALL not HSCT‑eligible, CD19+≥30%, measurable, ECOG 0–1, >12wk survival, washouts: steroids 2w, IS 4w, CNS tx 1w, tox ≤G1, contraception 12mo. Exclusions: CNS disease, chemo <2w or other trial <30d, HBV/HCV, HIV/syphilis, MI/UA <6mo, preg/nursing, neuroautoimmune, PI judgment, B‑ALL isolated EM relapse/recent CNS Tx.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Meta10-19, an autologous, gene‑modified CD19 CAR‑T cell therapy “metabolically armed” to enhance T‑cell metabolic fitness, persistence, and function in the tumor microenvironment. Mechanism: CAR recognition of CD19 on B cells triggers T‑cell activation and cytotoxicity (e.g., perforin/granzyme) with in vivo expansion, metabolic enhancement is intended to improve durability and antitumor activity. Pre-infusion lymphodepletion uses cyclophosphamide (alkylator) and fludarabine (purine antimetabolite). Targets: CD19 on malignant B cells (ALL, NHL) and T‑cell activation/persistence pathways.